Roche has reported positive topline data from the ongoing multi-part Phase I clinical trial of CT-996, an oral GLP-1 receptor agonist, to treat type 2 diabetes (T2D) and obesity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,